QFR Assessment and Prognosis After Nonculprit PCI in Patients With Acute Myocardial Infarction
- PMID: 37821181
- DOI: 10.1016/j.jcin.2023.08.032
QFR Assessment and Prognosis After Nonculprit PCI in Patients With Acute Myocardial Infarction
Abstract
Background: Complete revascularization using either angiography-guided or fractional flow reserve (FFR)-guided strategy can improve clinical outcomes in patients with acute myocardial infarction (AMI) and multivessel disease. However, there is concern that angiography-guided percutaneous coronary intervention (PCI) may result in un-necessary PCI of the non-infarct-related artery (non-IRA), and its long-term prognosis is still unclear.
Objectives: This study sought to evaluate clinical outcomes after non-IRA PCI according to the quantitative flow ratio (QFR).
Methods: We performed post hoc QFR analysis of non-IRA lesions of AMI patients enrolled in the FRAME-AMI (FFR Versus Angiography-Guided Strategy for Management of AMI With Multivessel Disease) trial, which randomly allocated 562 patients into either FFR-guided PCI (FFR ≤0.80) or angiography-guided PCI (diameter stenosis >50%) for non-IRA lesions. Patients were classified by non-IRA QFR values into the QFR ≤0.80 and QFR >0.80 groups. The primary outcome was a major adverse cardiac event (MACE), a composite of cardiac death, myocardial infarction, and repeat revascularization.
Results: A total of 443 patients (552 lesions) were eligible for QFR analysis. Of 209 patients in the angiography-guided PCI group, 30.0% (n = 60) underwent non-IRA PCI despite having QFR >0.80 in the non-IRA. Conversely, only 2.7% (n = 4) among 209 patients in the FFR-guided PCI group had QFR >0.80 in the non-IRA. At a median follow-up of 3.5 years, the rate of MACEs was significantly higher among patients with non-IRA PCI despite QFR >0.80 than in patients with deferred PCI for non-IRA lesions (12.9% vs 3.1%; HR: 4.13; 95% CI: 1.10-15.57; P = 0.036). Non-IRA PCI despite QFR >0.80 was associated with a higher risk of non-IRA MACEs than patients with deferred PCI for non-IRA lesions (12.9% vs 2.1%; HR: 5.44; 95% CI: 1.13-26.19; P = 0.035).
Conclusions: In AMI patients with multivessel disease, 30.0% of angiography-guided PCI resulted in un-necessary PCI for the non-IRA with QFR >0.80, which was significantly associated with an increased risk of MACEs than in those with deferred PCI for non-IRA lesions. (FFR Versus Angiography-Guided Strategy for Management of AMI With Multivessel Disease [FRAME-AMI] ClinicalTrials.gov number; NCT02715518).
Keywords: acute myocardial infarction; complete revascularization; fractional flow reserve; percutaneous coronary intervention; quantitative flow ratio.
Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures This trial is investigator initiated with grant support from Medtronic, BIOTRONIK, Chong Kun Dang Pharmaceutical, and JW Pharmaceutical. None of the funders were involved with the protocol development or study process, including site selection, management, data collection, and analysis of the results. The executive committee and all the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. Dr S.H. Lee received an institutional research grant from Abbott Vascular. Dr Hahn has received an institutional research grant from National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Republic of Korea; Abbott Vascular; Biosensors; Boston Scientific; Daiichi Sankyo; Donga-ST; and Medtronic Inc. Dr Gwon has received an institutional research grant from Abbott Vascular, Boston Scientific, and Medtronic Inc. Dr J.M. Lee has received an institutional research grant from Abbott Vascular, Boston Scientific, Philips Volcano, Terumo Corporation, Donga-ST, and Zoll Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment in
-
Heart of the Matter in Complete ACS Revascularization: Physiology Matters.JACC Cardiovasc Interv. 2023 Oct 9;16(19):2380-2382. doi: 10.1016/j.jcin.2023.09.007. JACC Cardiovasc Interv. 2023. PMID: 37821182 No abstract available.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous